Regeneron Pharmaceuticals Profit Margin

The latest profit margin for REGN is 27.86% as of June 2026. That compares with 31.37% in the prior-year period — down 11.2% year over year. That is above the Healthcare sector average of 14.34%. Investors often review this figure alongside Regeneron Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, REGN's profit margin moved from 31.37% to 27.86% — a 11.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Regeneron Pharmaceuticals's valuation or profitability profile.

Against Healthcare companies, REGN currently prints 27.86% for profit margin, while the sector average sits near 14.34%. That is roughly 94.2% above the sector mean. Large gaps often invite a closer look at Regeneron Pharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively Regeneron Pharmaceuticals converts resources into returns. At 27.86%, REGN may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 31.37% in the prior-year period — down 11.2% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting REGN's profit margin (27.86%), review year-over-year change from 31.37%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.